Eur J Endocrinol. 2018 May;178(5):R201-R214. doi: 10.1530/EJE-18-0007. Epub 2018 Feb 22.
Desmopressin is a vasopressin analogue selective for type 2 vasopressin receptors that mediate renal water retention. In contrast to the native hormone arginine vasopressin, a well-known ACTH secretagogue, desmopressin, exerts minimal or no activity on ACTH excretion. However, in a substantial proportion of patients with ACTH-dependent Cushing's syndrome (CS), desmopressin elicits an ACTH and cortisol response, which contrasts with the minimal responses obtained in healthy subjects. The mechanism underlying this paradoxical response involves upregulation of vasopressin type 3 and/or the aberrant expression of type 2 receptors by neoplastic ACTH-producing cells. This makes desmopressin administration a suitable test enabling the distinction between neoplastic from functional (formerly termed 'pseudo-Cushing syndrome') ACTH-dependent cortisol excess. Several studies have now established an adjunctive role of desmopressin in the initial diagnostic workup of CS. Despite some early data indicating that this test may also have a role in distinguishing between Cushing's disease (CD) and ectopic ACTH secretion, subsequent studies failed to confirm this observation. The ability of the paradoxical response to desmopressin to depict the presence of neoplastic ACTH-secreting cells was also exploited in the follow-up of patients with CD undergoing surgery. Loss of the desmopressin response, performed in the early postoperative period, was a good predictor for a favorable long-term outcome. Moreover, during follow-up, reappearance of desmopressin paradoxical response was an early indicator for recurrence. In conclusion, the desmopressin test is a valid tool in both the diagnosis and follow-up of patients with CD and should be more widely applied in the workup of these patients.
去氨加压素是一种选择性作用于 2 型血管加压素受体的血管加压素类似物,可介导肾脏水潴留。与作为一种知名的 ACTH 促分泌素的天然激素精氨酸血管加压素不同,去氨加压素对 ACTH 排泄几乎没有或没有活性。然而,在相当一部分依赖 ACTH 的库欣综合征(CS)患者中,去氨加压素会引起 ACTH 和皮质醇反应,与健康受试者获得的最小反应形成对比。这种矛盾反应的机制涉及到血管加压素 3 型的上调和/或肿瘤产生的 ACTH 细胞中 2 型受体的异常表达。这使得去氨加压素给药成为一种合适的测试方法,能够区分肿瘤性与功能性(以前称为“假性库欣综合征”)依赖 ACTH 的皮质醇过多。现在有几项研究已经确定了去氨加压素在 CS 的初始诊断中的辅助作用。尽管早期有一些数据表明,该测试也可能在区分库欣病(CD)和异位 ACTH 分泌方面具有作用,但随后的研究未能证实这一观察结果。去氨加压素的矛盾反应能够描绘出肿瘤性 ACTH 分泌细胞的存在,这一能力也被用于接受手术的 CD 患者的随访中。在术后早期进行的去氨加压素反应丧失是长期预后良好的良好预测指标。此外,在随访期间,去氨加压素矛盾反应的再次出现是复发的早期指标。总之,去氨加压素测试是 CD 患者诊断和随访的有效工具,应该更广泛地应用于这些患者的检查中。